CK Life Sciences Subsidiary Dogwood Therapeutics Reports Positive Interim Results in Halneuron® Phase 2b CINP Trial
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CK Life Sciences International (Holdings) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251223-11964335), on December 22, 2025, and is solely responsible for the information contained therein.